Published in Pharmacol Rep on December 10, 2008
Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology (2011) 2.79
Impact of diet on adult hippocampal neurogenesis. Genes Nutr (2009) 1.08
New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology (2012) 1.06
Protective effects of paeoniflorin against glutamate-induced neurotoxicity in PC12 cells via antioxidant mechanisms and Ca(2+) antagonism. Cell Mol Neurobiol (2010) 0.93
A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. J Neural Transm (Vienna) (2011) 0.91
Low dietary or supplemental zinc is associated with depression symptoms among women, but not men, in a population-based epidemiological survey. J Affect Disord (2011) 0.86
Probing the modulation of acute ethanol intoxication by pharmacological manipulation of the NMDAR glycine co-agonist site. Alcohol Clin Exp Res (2012) 0.85
Effects of nanoparticle zinc oxide on spatial cognition and synaptic plasticity in mice with depressive-like behaviors. J Biomed Sci (2012) 0.84
A consensus statement for safety monitoring guidelines of treatments for major depressive disorder. Aust N Z J Psychiatry (2011) 0.84
Chronic treatment with zinc and antidepressants induces enhancement of presynaptic/extracellular zinc concentration in the rat prefrontal cortex. Amino Acids (2010) 0.82
Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus. J Neural Transm (Vienna) (2010) 0.81
Concussions: What a neurosurgeon should know about current scientific evidence and management strategies. Surg Neurol Int (2012) 0.80
Nutrition and the psychoneuroimmunology of postpartum depression. Nutr Res Rev (2012) 0.79
Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model. PLoS One (2014) 0.78
Magnesium in CKD: more than a calcification inhibitor? J Nephrol (2014) 0.77
Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice. Metab Brain Dis (2016) 0.76
Alterations of Hair and Nail Content of Selected Trace Elements in Nonoccupationally Exposed Patients with Chronic Depression from Different Geographical Regions. Biomed Res Int (2017) 0.75
Quantification of serotonin O-sulphate by LC-MS method in plasma of healthy volunteers. Front Pharmacol (2014) 0.75
The Emerging Role for Zinc in Depression and Psychosis. Front Pharmacol (2017) 0.75
Investigational NMDA receptor modulators for depression. Expert Opin Investig Drugs (2011) 1.45
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther (2007) 1.41
Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol (2007) 1.22
Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch Med Sci (2013) 1.09
Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol (2004) 1.09
New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology (2012) 1.06
Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord (2009) 1.05
Polish version of the Hypomania Checklist (HCL-32) scale: the results in treatment-resistant depression. Eur Arch Psychiatry Clin Neurosci (2009) 1.03
NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol Biochem Behav (2007) 1.01
Lack of persistent effects of ketamine in rodent models of depression. Psychopharmacology (Berl) (2008) 1.01
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol (2013) 1.00
Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav (2005) 0.99
Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling. Neuropharmacology (2004) 0.99
GABAergic hypotheses of anxiety and depression: focus on GABA-B receptors. Drugs Today (Barc) (2005) 0.99
Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology (Berl) (2007) 0.97
Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull (2003) 0.96
The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J Affect Disord (2011) 0.96
The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.96
Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav (2002) 0.95
Antidepressant-like activity of zinc: further behavioral and molecular evidence. J Neural Transm (Vienna) (2008) 0.94
Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats. Eur J Pharmacol (2004) 0.93
Vitamin D and the central nervous system. Pharmacol Rep (2013) 0.92
mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology (2012) 0.92
(Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.92
Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. J Affect Disord (2010) 0.92
Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther (2007) 0.92
A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. J Neural Transm (Vienna) (2011) 0.91
Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem Int (2009) 0.91
Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems. Neuropharmacology (2010) 0.91
Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors. Eur J Med Chem (2012) 0.90
Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology (Berl) (2011) 0.90
Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Psychopharmacology (Berl) (2002) 0.90
Antepartum/postpartum depressive symptoms and serum zinc and magnesium levels. Pharmacol Rep (2006) 0.90
The role of zinc in neurodegenerative inflammatory pathways in depression. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.89
Zinc treatment induces cortical brain-derived neurotrophic factor gene expression. Eur J Pharmacol (2004) 0.89
The anxioselective agent 7-(2-chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) is more efficacious than diazepam at enhancing GABA-gated currents at alpha1 subunit-containing GABAA receptors. J Pharmacol Exp Ther (2006) 0.89
Immobility stress induces depression-like behavior in the forced swim test in mice: effect of magnesium and imipramine. Pharmacol Rep (2006) 0.88
On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology (Berl) (2010) 0.88
Zinc and depression. An update. Pharmacol Rep (2005) 0.88
Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu₄ receptor. Neuropharmacology (2012) 0.88
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci (2012) 0.87
The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling. Psychopharmacology (Berl) (2013) 0.86
Identification of novel serotonin transporter compounds by virtual screening. J Chem Inf Model (2014) 0.86
Effects of GABAB receptor ligands in rodent tests of anxiety-like behavior. Pharmacol Rep (2008) 0.86
Time course of zinc deprivation-induced alterations of mice behavior in the forced swim test. Pharmacol Rep (2012) 0.85
Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav (2004) 0.85
Interaction of zinc with antidepressants in the forced swimming test in mice. Pol J Pharmacol (2003) 0.85
Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity. Eur J Med Chem (2009) 0.85
NMDA/glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice. Pharmacol Rep (2008) 0.85
Zinc deficiency induces behavioral alterations in the tail suspension test in mice. Effect of antidepressants. Pharmacol Rep (2012) 0.84
Enhancement of antidepressant-like activity by joint administration of imipramine and magnesium in the forced swim test: Behavioral and pharmacokinetic studies in mice. Pharmacol Biochem Behav (2005) 0.84
The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents. Br J Pharmacol (2013) 0.84
[The position of psychooncology in contemporary psychiatry]. Psychiatr Pol (2009) 0.84
Reduced potency of zinc to interact with NMDA receptors in hippocampal tissue of suicide victims. Pol J Pharmacol (2003) 0.84
GPR39 up-regulation after selective antidepressants. Neurochem Int (2013) 0.84
NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opin Investig Drugs (2014) 0.84
[Emotional disorders in patients with cerebellar damage--case studies]. Psychiatr Pol (2014) 0.84
Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677. Cell Mol Neurobiol (2006) 0.84
Zinc-induced adaptive changes in NMDA/glutamatergic and serotonergic receptors. Pharmacol Rep (2010) 0.83
Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep (2008) 0.83
Risk factors of treatment resistance in major depression: association with bipolarity. J Affect Disord (2010) 0.83
Magnesium in depression. Pharmacol Rep (2013) 0.83
Oxidative stress markers in affective disorders. Pharmacol Rep (2013) 0.82
Chronic treatment with zinc and antidepressants induces enhancement of presynaptic/extracellular zinc concentration in the rat prefrontal cortex. Amino Acids (2010) 0.82
NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice. Pharmacol Rep (2011) 0.82